C. Michael Gibson/LinkedIn; Ulf Landmesser/FRIEDE SPRINGER
Cardiovascular
Prevention
Center Charité
Nov 9, 2025, 12:33
C Michael Gibson and Ulf Landmesser Discuss Insights from CLOSURE-AF trial
C Michael Gibson, President and CEO at Baim Institute for Clinical Research, shared on LinkedIn:
”Dr. Ulf Landmesser and I discuss the CLOSURE-AF trial:
In AF patients with high risk of stroke and bleeding, is LAA occlusion as effective and safe compared to optimal medical therapy?
View it here.”
Stay updated with Hemostasis Today.
-
Feb 22, 2026, 14:16Ilenia Calcaterra: From Representation to Intellectual Independence in Women in Science
-
Feb 22, 2026, 13:27Pete Stibbs: New AHA and ACC PE Guidelines Finally Align with Real Clinical Practice
-
Feb 22, 2026, 10:39Tagreed Alkaltham: Fibrinogen Concentrate Is a Deliberate Clinical Choice in Acute Bleeding
-
Feb 22, 2026, 09:38Abdulrahman Nasiri: Significant Shifts In The 2026 AHA/ACC Guidelines for Acute Pulmonary Embolism
-
Feb 22, 2026, 09:22Shiny K. Kajal: Not All Transfusion Reactions Are Immunohematologic Incompatibilities
-
Feb 22, 2026, 09:12Arun V J։ The Hidden Risks in Every Blood Bag
-
Feb 22, 2026, 08:56Parandzem Khachatryan։ How Hard Is It to Be a Mom, a Wife, a Professor, and a Doctor All at Once?
-
Feb 22, 2026, 08:46Anirban Sen Gupta Presents Bioinspired Platelet Surrogates at MTEC
-
Feb 22, 2026, 08:31Heghine Khachatryan: Advancing Care for Women and Girls with Bleeding Disorders is A Matter of Equity